Christopher H Van Dyck, MD

Professor of Psychiatry, Neurology, and Neuroscience; Director, Alzheimer's Disease Research Unit

Clinical Interests

  • Alzheimer Disease

Patient Care

Accepts new patients? Yes
Patient Type: Geriatric
Referrals: From patients or physicians

Patient Care Organizations

Dorothy Adler Geriatric Assessment Center

Psychiatry: Alzheimer's Disease Research Unit

Yale Medical Group

Clinical Trials

Conditions Study Title
Phase 2a Multi-Center Study of 18F-FDG PET Safety & Tolerability of AZD0530 in Mild AD
An Efficacy and Safety Trial of MK-8931 in Mild to Moderate Alzheimer's Disease (P07738) (EPOCH)
Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4) Study
Evaluate the efficacy and safety of T-817MA in patients with mild to moderate Alzheimer's Disease

Edit this profile

Contact Info

Christopher H Van Dyck, MD
Patient Care Locations
Yale Alzheimer's Disease Research Unit1 Church Street, Ste Suite 600
New Haven, CT 06510
View on map...
Adler Geriatric Assessment Center874 Howard Avenue
New Haven, CT 06519
View on map...
Mailing Address
Yale University School of Medicine
One Church Street

New Haven, CT 06510

Alzheimer's Disease Research Unit

Research Image 1

Frequency of psychosis by ApoE e4 carrier status and dementia severity. Mini Mental State Examination (MMSE) score was used to classify AD patients as mild (MMSE>19, n=103), moderate (MMSE=12-19, n=121), or severe (MMSE<12, n=42). Separate multiple logistic regression analyses were performed for each severity category, with presence of psychosis as dependent variable and the following independent variables (in addition to e4 carrier status): age, sex, educational attainment, and MMSE. *Only at the severe stage was the presence of e4 significantly associated with psychosis (odds ratio [OR]=16.61, 95% CI=2.11-130.51, P=.008). (From Zdanys KF , et al. 2007.)